OldManLogan
$LRMR Key takeaways summary:
1) Approval mid 2027, launch Q3 2027 in US; then launching in outside US markets around a year later I believe.
2) Nomla would be the only approved treatment for FA for patients under 16, so I don't doubt that they would get priority review
3) They have requested a PRV Voucher as a part of the BLA submission, which could bring in as much as $200M+ once approved
4) $130M in cash and company plans royalty deals or some strategic outlicensing to bridge that gap; so I'd expect to hear about a royalty deal soon...
7

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault14.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2Fcc%2F389.jpg)